Updates

December 5, 2019
HHS Secretary Alex Azar Touts White House Efforts to Cure Rare Diseases

Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access ... Read more
December 5, 2019December 5, 2019
Taltz Eases Disease Activity, Improves Quality of Life in nr-axSpA Patients, Phase 3 Trial Shows

Treatment with the anti-rheumatic drug Taltz (ixekizumab) leads to early and sustained reductions in pain, fatigue, and inflammation in people with non-radiographic axial spondyloarthritis ... Read more
December 2, 2019December 2, 2019
Rinvoq Pills Effectively Ease Symptoms in Hard-to-treat AS Patients, Phase 2/3 Trial Finds

Rinvoq (upadacitinib), an oral therapy recently approved for rheumatoid arthritis, was effective in treating adults with active ankylosing spondylitis (AS) who failed ... Read more
November 25, 2019November 25, 2019
Cosentyx Reduces Disease Activity and Pain in nr-axSpA Patients, Phase 3 Trial Shows

Treatment with Cosentyx (secukinumab) provided stable reduction in disease activity, as well as less pain and better mobility in people with non-radiographic ... Read more
November 21, 2019November 21, 2019
FDA Approves Abrilada, Biosimilar to Humira, for Adults with Ankylosing Spondylitis and Other Disorders

Abrilada (adalimumab-afzb), a biosimilar to Humira (adalimumab), has been approved by the U.S. Food and Drug Administration (FDA) to treat people with seven inflammatory ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

News

Erelzi Safe in AS, Eases Disease Activity in Rheumatoid Arthritis, Real-World Data Show
November 18, 2019November 18, 2019
Treatment with Erelzi (etanercept) is well-tolerated by people with ankylosing spondylitis (AS) and other ...
News

Rare Disease Film Festival Highlights Patient and Researcher Unity
November 14, 2019
Rare disease-themed videos glowed on a large screen before an audience of people in ...
News

Biogen Acquires Option for 5-year Extension on EU Marketing of Biosimilars for Ankylosing Spondylitis
November 14, 2019
Biogen has signed an agreement with Samsung Bioepis that includes an option of extending commercialization ...
News

Bimekizumab Found to be Safe and Show Sustained Efficacy for AS Treatment in Phase 2b Trial
November 11, 2019November 11, 2019
Treatment with the experimental therapy bimekizumab is safe and shows sustained efficacy over 48 ...
News

Continuous Use of NSAIDs Increases Hypertension Risk in AS Patients, Study Suggests
November 7, 2019November 7, 2019
Continuous use of non-steroidal anti-inflammatory drugs (NSAIDs) increases the risk of hypertension by 12% ...
News

Women Stop Using TNF Inhibitors Earlier and Switch More Often Than Do Men, Dutch Study Reports
November 4, 2019November 4, 2019
Women with ankylosing spondylitis (AS) stay with TNF inhibitor treatment for significantly shorter periods than men, ...

Likelihood of Gout May Be More Common in AS Patients, Study Reports
October 31, 2019October 31, 2019
Gout —a common, painful form of arthritis that causes swollen, red, hot, and stiff joints ...
Higher Dosage of Cosentyx for Ankylosing Spondylitis Approved in Europe
October 28, 2019October 28, 2019
The European Commission has approved a label update for Cosentyx (secukinumab) that will allow ...
Dutch Study Examines Factors that Contribute to Depression in AS
October 24, 2019October 24, 2019
Xeljanz Reduces Spinal Inflammation in One-third of AS Patients, Phase 2 Trial Shows
October 21, 2019October 21, 2019
SAA Joins with PatientPoint to Improve Disease Understanding, Treatment at Rheumatology Centers
October 17, 2019October 17, 2019
Ankylosing Spondylitis Psoriasis, Axial Psoriatic Arthritis Unrelated, Study Says
October 14, 2019October 14, 2019

Anti-TNF Therapy Slows Down AS Progression and Bone Loss, Study Says
October 10, 2019October 10, 2019
Anti-TNF therapies can halt disease progression and bone loss, and are associated with clinical ...
Cosentyx Effectively Lowers Disease Activity in nr-axSpA Patients Treated for 1 Year, Phase 3 Trial Reports
October 7, 2019October 7, 2019
AS Patients at Greater Risk of Other Inflammatory Diseases, Taiwanese Study Reports
October 3, 2019October 3, 2019
Anger Is a Natural Response to Chronic Illness
October 2, 2019September 27, 2019

Heat Therapy Called Moxibustion May Help People with Ankylosing Spondylitis, Short-term Study Finds
September 30, 2019September 30, 2019
Moxibustion, a form of heat therapy widely used in East Asia, given in combination ...
NORD 2019 Rare Disease Summit Set for Oct. 21-22 in Washington, DC
September 26, 2019
Depression More Common in People with Ankylosing Spondylitis, Analysis Shows
September 26, 2019September 26, 2019

A Wellness Journey - a Column by Lisa Marie Basile, Columns

Canceling on Friends: The Good, the Bad, and the Ugly
September 25, 2019September 30, 2019
It’s easy to say that if people can’t understand us, we should just forget ...
News

Cosentyx Shows Promise in Managing nr-axSpA Disease Activity, Phase 3 Trial Shows
September 23, 2019September 23, 2019
Treatment with Novartis’ Cosentyx (secukinumab) led to a significant reduction in disease activity compared to placebo in ...
News

Diffusion-weighted Imaging Useful to Identify Axial Spondyloarthritis
September 19, 2019September 19, 2019
A specific type of MRI called diffusion-weighted imaging is sensitive enough to identify patients ...
News

Biosimilar to Humira, IBI303, Shows Comparable Efficacy and Safety in Phase 3 Trial in China
September 16, 2019September 16, 2019
Treating ankylosing spondylitis (AS) patients with Humira (adalimumab) or a potential biosimilar called IBI303 had comparable ...
News

Qigong May Reduce AS Patients’ Fatigue, Morning Stiffness, Study Suggests
September 9, 2019September 9, 2019
Baduanjin qigong training, a traditional Chinese exercise, may reduce fatigue and morning stiffness in ...
News

FDA Approves Lilly’s Taltz for the Treatment of Active Ankylosing Spondylitis
September 5, 2019September 5, 2019
Eli Lilly‘s Taltz (ixekizumab) has been approved by the U.S. Food and Drug Administration ...

March 7, 2018March 7, 2018

Cosentyx Leads to Long-Term Improvement in AS Patients, Phase 3 Trial Shows

News

Results from a Phase 3 clinical trial show that treatment with Cosentyx (secukinumab) led to fast, significant, and sustained symptom improvement in patients with active ankylosing spondylitis (AS). Improvements were particularly noticeable in patients who had never ... Read more

Subscribe to our mailing list

Pin It on Pinterest